
A comprehensive meta-analysis of seven cohort studies suggests that DPP4 inhibitors (DPP4i) do not significantly impact the risk or progression of diabetic retinopathy (DR). These findings underscore the need for more extensive research to validate outcomes across diverse populations and standardized definitions of DR.
Like
Save
Share